The BDH1 Knockout SK-HEP-1 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population targeting the BDH1 gene in the human SK-HEP-1 host cell line. This population consists of a heterogeneous mix of cells harboring diverse loss-of-function mutations introduced via CRISPR/Cas9-mediated gene disruption, providing a robust model for studying the collective impact of BDH1 deficiency without the constraints of clonal selection. The polyclonal format preserves genetic diversity and reduces the risk of clonal artifacts, making it suitable for pooled functional studies, metabolic analyses, and high-throughput screening applications.
The host cell line, SK-HEP-1, was originally derived from the ascites of a patient with liver adenocarcinoma and is widely employed as a model of liver sinusoidal endothelial-like cells. These cells exhibit key endothelial characteristics, including barrier function, filtration, and angiogenic capacity, and are commonly used to investigate hepatic endothelial biology and tumor microenvironment interactions. SK-HEP-1 cells retain an adherent, cobblestone-like morphology and express typical endothelial markers, enabling reproducible experimentation in vascular biology and cancer research.
BDH1 (??-hydroxybutyrate dehydrogenase 1) encodes a mitochondrial enzyme that catalyzes the NAD+-dependent interconversion of acetoacetate and (R)-3-hydroxybutyrate, a critical reaction in ketone body utilization. Its activity is regulated by upstream metabolic signals, including transcriptional activation by PPARA and PPARG, hormonal control by insulin and glucagon, and induction by FGF21. Downstream, BDH1 activity directly modulates acetoacetate and 3-hydroxybutyrate levels, impacts the NAD+/NADH ratio, and influences epigenetic modifications such as histone acetylation and ??-hydroxybutyrylation. The enzyme functions within a multienzyme network, physically interacting with the mitochondrial membrane and functionally coupling with OXCT1 (succinyl-CoA:3-oxoacid CoA transferase), ACAT1 (acetyl-CoA acetyltransferase), and NADH. This pathway is central to the integrated regulation of ketone body flux, with HMGCS2 driving ketogenesis and OXCT1/ACAT1 facilitating terminal oxidation.
In the context of SK-HEP-1 cells, BDH1 knockout is expected to impair ketone body catabolism, thereby disrupting mitochondrial redox homeostasis and altering cellular energy substrate preference. Given the endothelial-like properties of the host line, this model is particularly relevant for investigating how metabolic reprogramming influences angiogenic signaling and barrier function within the liver microenvironment. The perturbation of NAD+/NADH equilibrium may further affect sirtuin activity and histone ??-hydroxybutyrylation, linking BDH1 loss to epigenetic dysregulation. These changes can be profiled in the SK-HEP-1 background to dissect the contribution of endothelial BDH1 to hepatocellular carcinoma progression and metabolic syndrome-associated vascular complications.
This polyclonal knockout resource enables a broad range of research applications, including the construction of metabolic enzyme knockout cancer models, dissection of ketone body metabolism in hepatic endothelium, and examination of BDH1??s role in angiogenesis. It is well-suited for metabolic reprogramming studies in hepatocellular carcinoma, where metabolite quantification by LC-MS, Seahorse mitochondrial stress testing, and NAD+/NADH luminescence assays can be combined with functional readouts such as tube formation assays. Standard characterization protocols include Western blotting for BDH1, RT-qPCR panels for metabolic genes, and flow cytometric assessment of mitochondrial mass. For further technical details, please contact Ascent Research.
